Addressing weight loss management in obese gout patients: guidance for future trials

Abstract

Obesity is widely recognized as being associated with both the onset and advancement of gout, exerting a detrimental effect on health outcomes in society. In the realm of gout management, theoretical frameworks support weight loss as a beneficial strategy for people impacted by overweight or obesity. Existing empirical evidence is limited to a handful of predominantly observational studies with low methodological rigor. A recent exploratory clinical trial which included 61 people with obesity and gout randomly allocated participants to either an intensive diet group (n = 29) or a control diet group (n = 32). After 16 weeks, a significant difference in body weight change was observed between the intensive diet group and the control diet group [−7.7 kg (95% confidence interval −10.7 to −4.7)]. Although the results leaned towards favoring a low-energy diet, differences in changes in serum urate (SU) levels and fatigue between the groups could not be confirmed. For the majority of individuals who lose weight a key challenge is long term maintenance. Novel agents such as glucagon-like peptide-1 receptor agonists (GLP-1Ras) have a role in weight loss and its maintenance. In this manuscript we propose what we consider the ideal target trial for weight loss in gout. We envision a two-year randomized trial with participants allocated to either a GLP-1Ra or placebo and evaluated and monitored over a two-year period.

Keywords

Gout / obesity / weight loss / management / evidence-based research / glucagon-like peptide-1 receptor agonist (GLP-1Ra)

References

[1] GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392: 1859-922.

[2] Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016; 388: 2039-52.

[3] Singh JA, Gaffo A. Gout epidemiology and comorbidities. Semin Arthritis Rheum. 2020; 50: S11-6.

[4] Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017; 76: 29-42.

[5] FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol. 2020; 72: 879-95.

[6] Larsson SC, Burgess S, Michaëlsson K. Genetic association between adiposity and gout: a Mendelian randomization study. Rheumatology (Oxford). 2018; 57: 2145-8.

[7] Choi HK, McCormick N, Lu N, Rai SK, Yokose C, Zhang Y. Population Impact Attributable to Modifiable Risk Factors for Hyperuricemia. Arthritis Rheumatol. 2020; 72: 157-65.

[8] Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med. 2005; 165: 742-8.

[9] Emmerson BT. Alteration of urate metabolism by weight reduction. Aust N Z J Med. 1973; 3: 410-2.

[10] Emmerson BT. The effect of weight reduction on urate metabolism. Adv Exp Med Biol. 1974; 41: 429-33.

[11] Asma Sakalli A, Küçükerdem HS, Aygün O. What is the relationship between serum uric acid level and insulin resistance?: A case-control study. Medicine (Baltimore). 2023; 102: e36732.

[12] Clamp LD, Hume DJ, Lambert EV, Kroff J. Enhanced insulin sensitivity in successful, long-term weight loss maintainers compared with matched controls with no weight loss history. Nutr Diabetes. 2017; 7: e282.

[13] Mills DW, Woolley DM, Ammori BJ, Chinoy H, Syed AA. Changes in Serum Urate Levels after Bariatric Surgery in Patients with Obesity: An Observational Study. Obes Surg. 2024; 34: 1737-41.

[14] Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al.; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023; 389: 2221-32.

[15] Choi HK, McCormick N, Yokose C. Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care. Nat Rev Rheumatol. 2022; 18: 97-111.

[16] Nielsen SM, Bartels EM, Henriksen M, Wæhrens EE, Gudbergsen H, Bliddal H, et al. Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. Ann Rheum Dis. 2017; 76: 1870-82.

[17] Li S, Feng L, Sun X, Ding J, Zhou W. Association between serum uric acid and measures of adiposity in Chinese adults: a cross-sectional study. BMJ Open. 2023; 13: e072317.

[18] Morillon MB, Nørup A, Singh JA, Dalbeth N, Taylor WJ, Kennedy MA, et al.; OMERACT Gout Working Group. Outcome reporting in randomized trials in gout: A systematic scoping review from the OMERACT gout working group assessing the uptake of the core outcome set. Semin Arthritis Rheum. 2023; 60: 152191.

[19] van Baak MA, Mariman ECM. Obesity-induced and weight-loss-induced physiological factors affecting weight regain. Nat Rev Endocrinol. 2023; 19: 655-70.

[20] Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012; 8: 728-42.

[21] Ard J, Fitch A, Fruh S, Herman L. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists. Adv Ther. 2021; 38: 2821-39.

[22] Ansari HUH, Qazi SU, Sajid F, Altaf Z, Ghazanfar S, Naveed N, et al. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis. Endocr Pract. 2024; 30: 160-71.

[23] Najafi S, Bahrami M, Butler AE, Sahebkar A. The effect of glucagon-like peptide-1 receptor agonists on serum uric acid concentration: A systematic review and meta-analysis. Br J Clin Pharmacol. 2022; 88: 3627-37.

[24] Christensen R, Zobbe K, Nielsen SM, Stamp LK, Henriksen M, Overgaard AF, et al. Weight Loss for Patients With Gout and Concomitant Obesity: A Proof-of-Concept Randomized Trial. Arthritis Rheumatol. 2024; 76: 806-12.

[25] Zaccardi F, Htike ZZ, Webb DR, Khunti K, Davies MJ. Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis. Ann Intern Med. 2016; 164: 102-13.

[26] Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015; 74: 1789-98.

[27] Stamp LK, Frampton C, Morillon MB, Taylor WJ, Dalbeth N, Singh JA, et al. Association between serum urate and flares in people with gout and evidence for surrogate status: a secondary analysis of two randomised controlled trials. Lancet Rheumatol. 2022; 4: e53-60.

[28] Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, et al.; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials. BMJ. 2023; 381: e073725.

[29] GUIDANCE DOCUMENT Multiple Endpoints in Clinical Trials: Guidance for Industry [Internet]. [Cited 2024 Jun 25]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/multiple-endpoints-clinical-trials

[30] Yadav K, Lewis RJ. Gatekeeping Strategies for Avoiding False-Positive Results in Clinical Trials With Many Comparisons. JAMA. 2017; 318: 1385-6.

[31] Detry MA, Lewis RJ. The intention-to-treat principle: how to assess the true effect of choosing a medical treatment. JAMA. 2014; 312: 85-6.

[32] White IR, Horton NJ, Carpenter J, Pocock SJ. Strategy for intention to treat analysis in randomised trials with missing outcome data. BMJ. 2011; 342: d40.

[33] Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York; John Wiley & Sons; 1987.

[34] Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al.; CHEERS Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ. 2013; 346: f1049.